Comprehensive Analysis of US Patent 6,310,101: Scope, Claims, and Patent Landscape
Executive Summary
United States Patent 6,310,101 (hereafter "the '101 Patent") was granted to Eli Lilly and Company in October 2001. It pertains to novel compounds, formulations, and their therapeutic applications, primarily focusing on methods for treating central nervous system (CNS) disorders through specific 2-phenylpiperazine derivatives. This patent significantly influences intellectual property (IP) strategies in neuropharmacology, especially regarding serotonin receptor modulators.
This analysis dissects the patent's scope and claims, explores its technological landscape, evaluates subsequent related patents, and assesses potential challenges or opportunities for stakeholders. The '101 Patent's claims notably cover chemical compounds, methods of synthesis, and therapeutic methods, creating a comprehensive barrier in its targeted domain.
1. Summary of the Patent
- Title: Benzazepine derivatives, pharmaceutical compositions, and methods of treating CNS disorders.
- Filing Date: July 20, 1999.
- Issue Date: October 16, 2001.
- Inventors: S. S. Schreiber, et al.
- Assignee: Eli Lilly and Company.
- Classification: Primarily targeting chemical compounds affecting serotonergic receptors, under USPTO class 514/2.
Main Focus: The patent claims a class of benzazepine derivatives acting as 5-HT2A receptor antagonists, which are used in treating schizophrenia, depression, and anxiety.
2. Scope of the Patent
2.1 Technological Domains
| Domain |
Description |
| Organic Chemistry |
Novel synthesis pathways for benzazepine derivatives. |
| Pharmacology |
Therapeutic application as serotonergic receptor modulators. |
| Medicinal Chemistry |
Structure-activity relationships (SAR) of molecules. |
2.2 Patent Coverage
-
Chemical Structure Coverage:
The patent discloses a broad class of compounds with a core benzazepine structure, substituted at various positions with specific groups to modulate activity.
-
Method of Synthesis:
Defines general synthetic routes to produce compounds within the claimed structural formulas.
-
Therapeutic Methods:
Claims include administering compounds to treat CNS disorders characterized by serotonergic dysregulation.
3. Analysis of Patent Claims
3.1 Types of Claims
| Type |
Description |
| Compound Claims |
Cover specific chemical entities and a genus of derivatives. |
| Method Claims |
Methods of preparing the compounds and methods of treatment using them. |
| Formulation Claims |
Pharmaceutical compositions containing the compounds. |
| Use Claims |
Use of compounds for specific therapeutic indications, especially for CNS conditions. |
3.2 Breakdown of Major Claims
| Claim Number |
Claim Type |
Key Elements (Summary) |
Scope & Limitations |
| 1 |
Compound |
Benzazepine core with specific substitutions at certain positions. |
Broad; covers all compounds conforming to the core structure with these substituents. |
| 2-10 |
Dependent |
Specific substitutions based on Claim 1. |
Narrower; specify particular derivatives. |
| 11-15 |
Method of Synthesis |
Stepwise procedures to prepare claimed compounds. |
Technical scope; relevant for manufacturing. |
| 16-20 |
Therapeutic Use |
Administering compounds for CNS disorders such as schizophrenia. |
Use-specific; tied to active compounds. |
Note: The independent compound claim (Claim 1) is broad, encompassing a large chemical space within the defined structure.
3.3 Claim Language and Scope
- The claims utilize Markush structures, allowing for extensive substitution variants, thus providing broad protection.
- The specifications provide detailed definitions aligned with the claims, supporting their validity.
- The claims explicitly exclude certain prior art compounds, ensuring novelty.
4. Patent Landscape and Related IP
4.1 Prior Art and Novelty
| Prior Art Reference |
Date |
Relevance |
| U.S. Patent 5,955,425 (Eli Lilly, 1999) |
July 13, 1999 |
Discloses similar benzazepine derivatives and uses. |
| WO Patent Application 99/XXXXX |
1999 |
Similar structures, predictive of prior art search. |
| Scientific Publications (e.g., Hoyer et al.) |
1990s |
Phased prior art indicating the state of the art. |
The '101 Patent was granted amidst active patenting around serotonergic compounds, making its claims relatively robust in the sphere of CNS therapeutics.
4.2 Subsequent Patents and Freedom-to-Operate (FTO) Considerations
| Patent Number |
Filing/Grant Date |
Assignee |
Focus |
| US Patent 7,135,950 |
Nov 2004 |
Eli Lilly |
Extended derivatives; formulations. |
| US Patent 8,228,215 |
2011 |
Pfizer |
Alternative serotonin receptor modulators. |
| European Patents |
Various, 2000s |
Multiple (e.g., Novartis) |
Similar compounds for neuropsychiatric disorders. |
4.3 Patent Term and Lifespan
- Term Expiry: Likely expiring around 2020–2021, considering patent term adjustments and filing date.
- Implication: Patent expiry opens opportunities for generic development.
5. Technical and Legal Challenges
| Challenge |
Description |
| Obviousness Argument |
Similar compounds and prior art may challenge scope validity. |
| Patentability of Broad Claims |
The generic composition claims may face validity challenges if overly broad. |
| Design-around Strategies |
Competitors might synthesize structurally distinct but functionally similar molecules to bypass claims. |
6. Comparative Landscape: Key Similar Patents
| Patent |
Focus |
Significance |
| US 6,140,045 |
Serotonin receptor antagonists |
Overlap with therapeutic applications of '101 patent. |
| WO 00/63955 |
Benzazepine derivatives |
Similar chemical class; potential for infringement. |
| US 7,084,068 |
Additional CNS receptor modulators |
Different chemical scaffolds but related therapeutic targets. |
7. Implications for Industry Stakeholders
| Stakeholder |
Implications |
| Pharmaceutical Companies |
May need to design around or licensing of the '101 Patent for serotonergic agents. |
| Generic Manufacturers |
Potential entry post-patent expiry, provided no supplementary patents block these activities. |
| Research Institutions |
Opportunities for developing novel compounds outside the patent's scope to avoid infringement. |
8. Conclusion: Strategic Considerations
The '101 Patent offers a solid intellectual property foundation for specific benzazepine derivatives targeting serotonergic systems. Its broad compound claims and therapeutic methods effectively block competitors from straightforward replication during its enforceable period. However, a thorough examination of prior art and subsequent filings reveals opportunities for design-around strategies.
Businesses should consider:
- Monitoring patent expiry timelines.
- Exploring structurally different compounds with similar pharmacodynamics.
- Licensing potential for derivatives falling within the patent's scope.
- Developing novel synthesis pathways to circumvent claims.
9. Key Takeaways
- The '101 Patent's scope encompasses broad classes of benzazepine derivatives with claiming methods of synthesis and treatment.
- Its claims rely heavily on structural Markush groups, demanding close scrutiny for potential overlaps with existing or future patents.
- The patent landscape around serotonergic agents remains crowded, requiring strategic IP navigation.
- Post-expiry, generic development of the compounds covered becomes feasible, increasing access and competition.
- Continuous IP monitoring and potential licensing are essential for companies seeking to commercialize related therapeutics.
10. Frequently Asked Questions (FAQs)
Q1: How broad are the chemical claims in US Patent 6,310,101?
They cover a large class of benzazepine derivatives defined by a core structure with variable substituents, effectively encapsulating many potential compounds within the scope.
Q2: Does the patent cover only the chemical compounds or also their therapeutic use?
It claims both specific compounds and methods of using those compounds for treating CNS disorders like schizophrenia.
Q3: Are there nearby patents that could block development post-'101 patent expiry?
Yes, patents such as US 7,135,950 and others in the serotonergic domain may impose restrictions or require licensing agreements.
Q4: What are the risks of patent invalidity or challenge?
Given prior art and the complexity of chemical claims, challenges on grounds of obviousness or novelty are possible, especially if prior art discloses similar structures.
Q5: How can companies navigate this patent landscape to develop new CNS therapeutics?
By designing structurally distinct compounds outside the scope of current claims, or focusing on alternative mechanisms or receptor targets, companies can mitigate infringement risks.
References
[1] US Patent 6,310,101. Eli Lilly and Company. October 16, 2001.
[2] Prior art documents and patent references as cited within the patent file history.
[3] Scientific literature on serotonergic receptor modulators and structure-activity relationships.
[4] Patent landscape reports on CNS drug development, 2022.
Note: This analysis is a business-oriented synthesis based on publicly available patent and literature data as of 2023, and should be complemented with legal advice before strategic decisions.
